Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 366
- Registration Number
- NCT03754803
- Locations
- 🇩🇪
GSK Investigational Site, Weimar, Germany
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 32
- Registration Number
- NCT03682848
- Locations
- 🇹🇭
GSK Investigational Site, Chiang Mai, Thailand
Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 97
- Registration Number
- NCT03639311
- Locations
- 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada
A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 14
- Registration Number
- NCT03575962
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 250
- Registration Number
- NCT03564613
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 209
- Registration Number
- NCT03518060
- Locations
- 🇩🇪
GSK Investigational Site, Weimar, Germany
GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV
- Conditions
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT03462810
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 743
- Registration Number
- NCT03446573
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 36
- Registration Number
- NCT03441984
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 48
- Registration Number
- NCT03422172
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath